ArticleImmunologic research2020
Anti-IL-6 receptor monoclonal antibody as a new treatment of endometriosis.
Article in Immunologic research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Alterations in Cellular Immunity in Patients With Endometriosis: Systematic Review and Meta-Analysis.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Pooled it
- Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances.Journal of clinical medicine · 2026Review
- Targeting the Immune Network in Endometriosis: A Comprehensive Review of Pathogenesis, Immunomodulation, and Emerging Therapies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Molecular Insights Into Endometriosis for Early Detection and Therapeutic Targets.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Emerging signal transduction pathways and the role of bacterial extracellular vesicles linked to the pathogenesis of endometriosis.Communications medicine · 2026Review
- MicroRNAs in endometriosis: bioinformatics resources, machine learning strategies, and multi-omics perspectives.Journal of translational medicine · 2026Review
- Endometriosis as a Systemic and Complex Disease: Toward Phenotype-Based Classification and Personalized Therapy.International journal of molecular sciences · 2026Review
- Immune Suppression and Somatic Mutation in Endometriosis - An Opportunity for Personalized Immunotherapy.International journal of women's health · 2026Article
- IL-6 Inhibits Invasion in a Murine Model of Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Temporal dynamics of uterine immune microenvironment remodeling in a murine model of adenomyosis.Molecular human reproduction · 2025Article
- Immunohistochemical examination of CD163 and TROP2 expression levels in ovarian endometriosis.Journal of molecular histology · 2025Article
- Co-Occurrence of Endometriosis with Systemic Lupus Erythematosus: Genetic Aspects.International journal of molecular sciences · 2025Review
- Evaluation of Proinflammatory Cytokines Concentrations in Plasma, Peritoneal, and Endometrioma Fluids in Women Operated on for Ovarian Endometriosis-A Pilot Study.International journal of molecular sciences · 2025Article
- Bioinformatics Analysis of Hypoxia-Related Mechanisms in Endometriosis: DDR2 as a Potential Diagnostic and Therapeutic Biomarker.BioMed research international · 2025Article
- Relationship Between Inflammation-Nutrition Composite Indices and Ovarian Endometrioma: A Retrospective Observational Study.Journal of inflammation research · 2025Article
- Endometriosis as an immune-mediated disease: pathogenetic mechanisms and therapeutic strategies.Frontiers in immunology · 2025Review
- TET3-overexpressing macrophages promote endometriosis.The Journal of clinical investigation · 2024Article
- New Potential Pharmacological Options for Endometriosis Associated Pain.International journal of molecular sciences · 2024Review
- The Known, the Unknown and the Future of the Pathophysiology of Endometriosis.International journal of molecular sciences · 2024Review
- Protective effects ofFood science & nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many pro-inflammatory cytokines especially tumor necrotic factor alpha (TNFα), interleukin (IL)-1β, and IL-6 have crucial role in the pathogenesis of endometriosis. In this study, we investigated the immune-modulatory role of humanized anti-IL-6 receptor monoclonal antibodies in the treatment of endometriosis. This is a prospective, randomized, controlled, blinded study in which Sprague Dawley rats were used as animal model of endometriosis. Animals were randomly divided into two groups, a test group which received tocilizumab (Actemra; Roche, Switzerland) and a control group which received saline. Afterwards, a comparison was done between the eutopic and ectopic endometrium that was excised from both groups, histopathologically and immune-histochemically. Histopathologic assessment and immune-histochemical staining were performed using antibodies against IL-6. Tocilizumab significantly suppressed the volume of endometriotic lesions compared with non-treated rats (P = 0.006) and atrophied the ectopic endometrial-like epithelium (in 42.8% of treated rats vs 0% in the control group). Tocilizumab also decreased the anti-IL-6 receptor immune-histochemical staining intensity in ectopic endometrium (from non to +++ in the test group vs ++ or more in the control group), with no apparent difference in the eutopic one reflecting the down-regulation of IL-6-producing cells in ectopic endometriotic lesions. In rats with induced endometriosis, anti-IL-6 receptor monoclonal antibodies could offer a new horizon of usage of this immune-modulatory biologic drug, used in other autoimmune diseases, in treatment of endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.